Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease


Fibrogen, Inc., San Francisco, California

Received January 16, 2020; accepted May 13, 2020

ABSTRACT

Anemia of chronic kidney disease (CKD) is a multifactorial disorder caused by impaired erythropoietin (EPO) production and altered iron homeostasis associated with inflammation. Hypoxia-inducible factor (HIF) is a transcription factor that stimulates erythropoiesis via a coordinated response involving increased EPO production and enhanced iron availability for Hb synthesis. HIF degradation is regulated by HIF-prolyl hydroxylase (HIF-PH) enzymes. We hypothesized that roxadustat, an orally available small-molecule inhibitor of HIF-PH, would increase EPO production and promote erythropoiesis in animal models of anemia. In cells, roxadustat increased both HIF-1α and HIF-2α proteins, leading to an increase in EPO production, even in the presence of EPO-suppressing inflammatory cytokines. Roxadustat administered intermittently to healthy rats and cynomolgus monkeys increased circulating EPO levels, reticulocytes, blood Hb, and hematocrit in a dose-dependent manner. Roxadustat corrected anemia in a rat model of CKD after five-sixth nephrectomy and in a rat model of anemia of inflammation with impaired iron metabolism induced by peptidoglycan-polysaccharide (PG-PS). In the PG-PS model, roxadustat significantly decreased hepatic expression of hepcidin, a hormone responsible for iron sequestration and functional iron deficiency, and increased expression of two genes involved in duodenal iron absorption: divalent metal transporter 1 and duodenal cytochrome b. In conclusion, by activating the HIF pathway, roxadustat increased EPO production, elevated Hb, corrected anemia, and improved iron homeostasis. The coordinated erythropoietic response stimulated by roxadustat, involving both EPO production and mobilization of iron stores, makes this compound a promising treatment of anemia of CKD and anemia associated with functional iron deficiency.

SIGNIFICANCE STATEMENT

Roxadustat is a novel orally available small-molecule inhibitor of HIF prolyl hydroxylase enzymes that reversibly stabilizes HIF-α, thus activating transcription of HIF-dependent genes, including EPO and regulators of iron homeostasis. Activation of the HIF pathway by roxadustat induces erythropoiesis in healthy rats and monkeys and corrects experimentally induced anemia in rats. The coordinated erythropoietic response that increases EPO production and mobilizes iron stores makes roxadustat a promising treatment for anemia of chronic kidney disease and anemia associated with functional iron deficiency.

Introduction

Anemia is a frequent and serious complication of chronic kidney disease (CKD) that affects millions of patients worldwide (Thomas et al., 2008; Kassem, et al., 2014; Stauffer et al., 2014). Anemia of CKD contributes to decreased quality of life and increased risk of morbidity and mortality (Finkelman et al., 2009; Thorp et al., 2009). Key factors responsible for anemia of CKD are a relative deficiency in erythropoietin (EPO) production and a decrease in iron...
availability for Hb synthesis (Yilmaz et al., 2011; Babitt and Lin, 2012; Locatelli et al., 2017). Currently, anemia of CKD is managed by iron supplementation and, in more severe cases, by administration of supraphysiologic doses of erythropoiesis-stimulating agents (ESAs), such as human recombinant EPO, in combination with adjuvant iron therapy (Biggar and Kim, 2017). However, some patients are hyporesponsive to ESAs and need even larger doses because of functional iron deficiency associated with inflammation (MacDougall and Cooper, 2005; Adamson, 2009; Yilmaz et al., 2011). High doses of ESAs increase the risk of serious adverse events, including death, myocardial infarction, congestive heart failure, and stroke (Szczech et al., 2008; Pfeffer et al., 2009). Thus, to effectively treat anemia of CKD, new therapies need to address both impaired EPO production and functional iron deficiency (Locatelli et al., 2017).

The observation that low blood oxygen levels lead to increased EPO production was made decades ago (Prentice and Mirand, 1961; Naets, 1963), but the transcription factors responsible for this hypoxic response were not identified until the 1990s (Semenza and Wang, 1992; Wang and Semenza, 1995; Wang et al., 1995; Tian et al., 1997). Since then, these hypoxia-inducible factors (HIFs) have been found to be part of an oxygen-sensing pathway that is evolutionarily conserved among metazoans (Kaelin, 2005; Kaelin and Ratcliffe, 2008). HIFs function as heterodimers comprising an oxygen-regulated α-subunit and a constitutively expressed β-subunit. There are two major HIF-α isoforms, HIF-1α and HIF-2α, both of which dimerize with the same β-subunit to form functional HIF-1 and HIF-2 transcription factors, respectively. In the presence of oxygen, HIF-α subunits are hydroxylated on specific proline residues by a family of HIF prolyl hydroxylase (HIF-PH) enzymes comprising three isoforms: PHD1 (Egl nine homolog [EGLN]2), PHD2 (EGLN1), and PHD3 (EGLN3) (Kaelin and Ratcliffe, 2008; Myllyharju, 2013). This hydroxylation enables binding of the von Hippel-Lindau protein, a component of an E3 ubiquitin ligase, which ubiquitinates HIF-α to target it for proteasomal degradation. HIF-PH enzymes require α-ketoglutarate (αKG) and oxygen as cosubstrates. Thus, when oxygen levels fall, the activity of HIF-PH enzymes decreases, causing HIF-α subunits to accumulate and dimerize with HIF-β to form functional transcription factors. This process induces adaptive changes in gene expression that either enhance oxygen delivery (e.g., erythropoiesis) or promote survival in a hypoxic environment (Kaelin, 2005; Fong and Takeda, 2008; Kaelin and Ratcliffe, 2008). A fourth oxygen and αKG-dependent enzyme, known as factor inhibiting HIF-1α (FIH), hydroxylates HIF-α subunits on an asparagine residue. Hydroxylation by FIH inhibits binding of transcriptional coactivators to HIF-α and thus limits HIF transcriptional activity (Mahon et al., 2001; Lando et al., 2002a,b).

HIF stimulates erythropoiesis via a coordinated response that involves increases in endogenous EPO and enhanced availability of iron for Hb synthesis. HIF directly regulates expression of the EPO gene (Haase, 2010; Bunn, 2013), as well as genes encoding proteins involved in iron absorption (e.g., divergal metal transporter 1 (DMT1), duodenal cytochrome b (DCYTB)), iron transport (e.g., transferrin), iron mobilization (e.g., ferroportin), and iron recycling (e.g., heme oxygenase-1) (Haase, 2010). Furthermore, activation of the HIF pathway reduces levels of hepcidin, the hormone responsible for iron homeostasis. Elevated hepcidin, which is driven by chronic inflammation, leads to sequestration of iron in enterocytes, macrophages, and hepatocytes, thereby causing functional iron deficiency. Downregulation of hepcidin by activation of the HIF pathway releases iron trapped in cells, thus increasing iron availability for Hb synthesis (Peyssonnaux et al., 2008).

Roxadustat was developed as an orally active inhibitor of the HIF-PH enzymes. In this series of in vitro and in vivo studies, we studied the effects of roxadustat on activation of the HIF pathway, EPO secretion, and stimulation of erythropoiesis in normal rats and monkeys. We also evaluated the ability of roxadustat to correct anemia in two different rodent models. The five-sixth nephrectomy model was used to demonstrate that roxadustat can correct anemia of CKD. The model of anemia of chronic disease (ACD) induced by administration of proteoglycan-polysaccharide (PG-PS) was used to show that roxadustat can reverse anemia associated with inflammation and functional iron deficiency.

**Materials and Methods**

**In Vitro Studies**

**HIF Hydroxylase Enzyme Assays.** Activity of HIF-PH and FIH enzymes was determined based on the capture of 14CO2 released by the decarboxylation of [1-14C]αKG (Zhang et al., 1999). Reaction mixtures included Fe(SO4) (Sigma-Aldrich, St. Louis, MO), [1-14C]αKG (Perkin Elmer, Waltham, MA), nonlabeled αKG (Sigma-Aldrich), ascorbate (Sigma-Aldrich), peptide substrate (PHD1,2,3: acetyl-DLDLEMLAPYIPMDDDFQL-amide, FIH: DESGLPQLTSYDCEV-NAPIQGSRNLLQGEELRL-biotin) (Mimotopes, Mulgrave, Australia), and catalase (catalog number C100; Sigma-Aldrich) in 50 mM HEPES buffer (Corning Life Sciences, Tewksbury, MA), pH 7.4. Enzymatic reactions were initiated by addition of full-length recombinant human HIF-PH or FIH enzyme to the reaction mixture (Hirsilä et al., 2005). The reactions were performed in 96-well microtiter plates (100 μl total assay volume) (Thomas Scientific, Santa Clara, CA). 14CO2 was captured on a glass fiber filter paper (Inotech Biosystems International, Brandon, FL) soaked with saturated Ba(OH)2 that was laid on top of the 96-well plate. A microtiter plate sealer film (Thermal Seal Insulating Glass, Uxbridge, MA) was applied to the filter paper. The plate and filter paper were sandwiched between two custom-made aluminum plates (Advanced Component Manufacturing, Burlingame, CA) and transferred to a 37°C oven for 1 to 2 hours. After incubation, the filter paper was dried in a 103°C oven for 40–60 minutes. To determine percent turnover, aliquots of the reaction mixture were spotted onto the filter paper, and the filter paper was dried again. The dry filter paper was exposed to a storage phosphor screen for 24–72 hours, and the images were recorded with a Typhoon FLA 7000 imager (Amersham Biosciences, Piscataway, NJ). Integrated spot intensities corresponding to control reactions lacking the enzyme were subtracted from integration results for enzyme-containing reactions, and data were converted to enzyme-dependent percent 14CO2 release. All enzymatic reactions were run in duplicate.

To determine the IC50 of roxadustat for the HIF-PH and FIH enzymes, a 3-fold dilution series of roxadustat (FG-4592; FibroGen, Inc.) was prepared and added to the reaction mixture (final 1% DMSO, v/v) prior to addition of the enzyme. The final reagent concentrations were as follows: 1 μM Fe(SO4)3, 3 μM [1-14C]αKG, 97 μM nonlabeled αKG, 1 mM ascorbate, 50 μM peptide substrate, and ~2 μM catalase. IC50 values were determined by nonlinear fitting using GraFit version 7.0 (Erithacus Software, UK).

To calculate the kinetic parameters for PHD2, turnover velocity was measured as a function of αKG concentration at varying concentrations of roxadustat. Nonlinear regression analysis was applied to the
Michaelis-Menten equation to obtain apparent $V_{\text{max}}$ and $K_m$ using GraFit version 7.0. Double-reciprocal plots of the nonlinear best fits at varying roxadustat concentrations were used to evaluate the mode of inhibition, whereas linear fitting of the apparent $K_m/V_{\text{max}}$ versus roxadustat concentration was used to determine $K_i$.

**Cell Culture.** Hep3B cells (catalog number HB-8064; American Type Culture Collection, Manassas, VA) were maintained in Dulbecco’s modified Eagle’s medium (catalog number 10-013-CM; Corning Life Sciences) containing 10% FBS (catalog number SH30071.03; GE Healthcare Life Sciences, Pittsburgh, PA) under 10% CO₂ conditions at 37°C. Treatment medium for Hep3B cells was Dulbecco’s modified Eagle’s medium containing 0.5% FBS (D0.5). HK-2 cells (catalog number CRL-2180; American Type Culture Collection) were maintained in Keratinocyte Serum-Free Medium supplemented with epidermal growth factor and bovine pituitary extract (catalog number 17005-042; Thermo Fisher Scientific, Waltham, MA) under 5% CO₂ conditions at 37°C. Treatment medium for HK-2 cells was the same as maintenance medium.

**Analysis of HIF-1α and HIF-2α Stabilization in Hep3B and HK-2 Cells.** Hep3B cells and HK-2 cells were plated into 10-cm dishes at 2 × 10⁶ cells or 8 × 10⁵ cells per dish, respectively. The next day, the cells were treated with 3–30 μM roxadustat or vehicle control (0.15% DMSO) in their respective treatment media. After 3 hours, the cell monolayer was lysed with radio immunoprecipitation assay lysis buffer (Teknova, Hollister, CA) supplemented with Halt protease inhibitors (Thermo Fisher Scientific), and whole-cell lysates were collected.

**Analysis of HIF-1α Protein Levels in Hep3B Cells After Removal of Roxadustat.** Hep3B cells were plated into 6-cm dishes at 1 × 10⁶ cells per well. The next day, the cells were treated with 30 μM roxadustat or vehicle control (0.15% DMSO) in treatment medium. After 3 hours, the medium was removed, cells were washed, and fresh D0.5 medium (without roxadustat or vehicle control) was added. Whole-cell lysates, generated in radio immunoprecipitation assay lysis buffer, were collected immediately (time “0”), 15, 30, or 60 minutes after removal of roxadustat.

**Western Blot Analyses.** Protein concentrations of whole-cell lysates were measured using the Pierce BCA protein assay kit (Thermo Fisher Scientific). Equal protein was loaded for each sample onto electrophoresis gels. The samples were resolved by SDS-PAGE, transferred to a polyvinylidene difluoride membrane (Invitrogen, Carlsbad, CA), and immunoblotted with HIF-1α (1:1000 dilution, catalog number 610959, lot number 23681; BD Biosciences, San Jose, CA) or HIF-2α (1:1000 dilution, catalog number AF2886, lot number VEA0312021; R&D Systems, Minneapolis, MN) antibodies. The horseradish peroxidase (HRP)-conjugated secondary antibodies used were anti-mouse HRP (1:5000 dilution, catalog number 416520; Invitrogen) and anti-goat HRP (1:5000 dilution, catalog number 416120; Invitrogen), respectively. Bands were visualized using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) and 0.1% polysorbate 80 (Avantor Performance Materials, Radnor, PA). Bands were quantified using ImageJ software (National Institutes of Health, Bethesda, MD). The same dose was administered orally by gavage in a volume of 5 ml/kg (4 mg/ml suspension in 0.5% sodium carboxymethylcellulose and 0.1% Tween 80). 30 mg/kg was administered orally intravenously via the tail vein at a volume of 0.5 ml/kg (40 mg/ml in a saline solution with pH adjusted by NaOH for solubility). Blood samples were collected at times ranging from 0.1 to 48 hours postdose for determination of plasma roxadustat concentration by liquid chromatography-mass spectrometry.

The time course of EPO secretion in plasma after roxadustat administration was determined in male Sprague-Dawley rats ($n = 3$). Procedures were carried out at FibroGen, Inc. (San Francisco, CA) and approved by the Institutional Animal Care and Use Committee at FibroGen, Inc. Animals were housed individually in standard shoebox-style rat cages. Fluorescent lighting was provided for 12 hours per day between 7:00 AM and 7:00 PM. Temperature was maintained between 20 to 26°C and humidity ranging from 40% to 70%. Animals weighed 275–311 g at the time of drug administration. A dose of 30 mg/kg was administered orally by gavage in a volume of 5 ml/kg (4 mg/ml suspension in 0.5% sodium carboxymethylcellulose and 0.1% Tween 80). Animals weighed 311–318 g at the time of dosing. A single dose of 30 mg/kg was administered orally in a volume of 5 ml/kg (4 mg/ml suspension in 0.5% sodium carboxymethylcellulose (Spectrum Chemical, Gardena, CA) and 0.1% polysorbate 80 (Avantor Performance Materials, Radnor, PA)). Blood samples were collected at regular intervals up to 24 hours postdose for determination of plasma EPO and roxadustat concentrations. Plasma EPO was measured using the Quantikine Mouse Erythropoietin ELISA kit (R&D Systems).

The erythropoietic effect of roxadustat was investigated in male Sprague-Dawley rats (Crl: CD) purchased from Charles River Laboratories Japan, Inc. (Hino Breeding Center, Japan). All procedures were carried out in the animal facility at Nihon Bioresource, Inc. (Hashima, Japan) following the Basic Guidelines for the Use of Experimental Animals in Institutions under the jurisdiction of the Japanese Ministry of Health, Labor and Welfare and the Guidelines for Management and Welfare of Experimental Animals (Nihon Bioresource, Inc.). The animals were kept on a 12-hour light/dark cycle (lighting: 6:00 AM to 6:00 PM) in an animal holding room set at approximately 23°C (range: 21.8–24.1°C) and 55% humidity (range: 44.0%–61.1%) with filtered fresh air changes of 12 times per hour. The animals were housed individually in stainless-steel suspended cages.

**Roxadustat Induction of Secreted EPO in Hep3B Cells.** Hep3B cells were plated into 96-well plates at 2 × 10⁴ cells per well. The next day, cells were treated with 3–60 μM roxadustat or vehicle control (0.15% DMSO) in treatment medium. After 72 hours, conditioned media were collected for EPO analysis by sandwich immunoassay (catalog number DEP00; R&D Systems).

**Effects of Inflammatory Cytokines on Secreted EPO in the Presence or Absence of Roxadustat in Hep3B Cells.** Hep3B cells were plated into 96-well plates at 5.5 × 10⁴ cells per well. The next day, cells were treated with tumor necrosis factor (TNFα) (catalog number 210-TA; R&D Systems), interleukin (IL)-1β (catalog number 201-LB; R&D Systems), or PBS vehicle control plus either 3–30 μM roxadustat or 0.15% DMSO in treatment medium. After 72 hours, conditioned media were collected for EPO analysis by sandwich immunoassay (catalog number K15122B; Meso Scale Diagnostics, Rockville, MD).

**In Vivo Studies.**

**Procedures in Normal Rats and Monkeys.** Pharmacokinetic parameters for roxadustat were determined in normal male Sprague-Dawley rats ($n = 4$ per group) of approximately 8 weeks of age under fasting conditions (Tsukuba Laboratories, Nemoto Science Co., Ibaraki, Japan). All procedures were approved by the Institutional Animal Care and Use Committee of Nemoto Science. Animals were housed individually in metal cages and kept on a 12-hour light/dark cycle (lighting: 7:00 AM to 7:00 PM) in an animal holding room with temperature ranging from 20 to 26°C and humidity ranging from 40% to 70%. Animals weighed 275–311 g at the time of drug administration. A dose of 20 mg/kg was administered orally by gavage in a volume of 5 ml/kg (mg/ml suspension in 0.5% sodium carboxymethylcellulose and 0.1% Tween 80). The same dose was administered intravenously via the tail vein at a volume of 0.5 ml/kg (40 mg/ml in a saline solution with pH adjusted by NaOH for solubility). Blood samples were collected at times ranging from 0.1 to 48 hours postdose for determination of plasma roxadustat concentration by liquid chromatography-mass spectrometry.

The time course of EPO secretion in plasma after roxadustat administration was determined in male Sprague-Dawley rats ($n = 3$). Procedures were carried out at FibroGen, Inc. (San Francisco, CA) and approved by the Institutional Animal Care and Use Committee at FibroGen, Inc. Animals were housed individually in standard shoebox-style rat cages. Fluorescent lighting was provided for 12 hours per day between 7:00 AM and 7:00 PM. Temperature was maintained between 20 and 22°C, and humidity was maintained between 35% and 50%. Rodent Laboratory Diet (catalog number 5001; PMI Feeds, Inc., St Louis, MO) was withheld overnight before dosing and made available 4 hours postdose. Tap water was available ad libitum. Animals weighed 311–318 g at the time of dosing. A single dose of 30 mg/kg was administered orally in a volume of 5 ml/kg (4 mg/ml suspension in 0.5% sodium carboxymethylcellulose (Spectrum Chemical, Gardena, CA) and 0.1% polysorbate 80 (Avantor Performance Materials, Radnor, PA)). Blood samples were collected at regular intervals up to 24 hours postdose for determination of plasma EPO and roxadustat concentrations. Plasma EPO was measured using the Quantikine Mouse Erythropoietin ELISA kit (R&D Systems).

The erythropoietic effect of roxadustat was investigated in male Sprague-Dawley rats (Crl: CD) purchased from Charles River Laboratories Japan, Inc. (Hino Breeding Center, Japan). All procedures were carried out in the animal facility at Nihon Bioresource, Inc. (Hashima, Japan) following the Basic Guidelines for the Use of Experimental Animals in Institutions under the jurisdiction of the Japanese Ministry of Health, Labor and Welfare and the Guidelines for Management and Welfare of Experimental Animals (Nihon Bioresource, Inc.). The animals were kept on a 12-hour light/dark cycle (lighting: 6:00 AM to 6:00 PM) in an animal holding room set at approximately 23°C (range: 21.8–24.1°C) and 55% humidity (range: 44.0%–61.1%) with filtered fresh air changes of 12 times per hour. The animals were housed individually in stainless-steel suspended cages.
and were given free access to solid food (CRF-1; Oriental Yeast Co., Ltd., Japan) and tap water. Animals weighed 287–338 g at study initiation and were assigned to treatment groups such that the mean body weight was similar among groups (n = 8 per group). Animals were then treated orally by gavage three times per week for 29 days with vehicle or 6.25, 12.5, 25, or 50 mg/kg roxadustat formulated in 0.5% sodium carboxymethylcellulose (Maruishi Pharmaceuticals, Japan) and 0.1% Tween 80 (Sigma-Aldrich Japan, Japan). The day before administration of the first dose, and before dosing on days 4, 9, 15, and 29 of treatment, about 300 μl of venous blood was collected to measure blood Hb concentration, hematocrit, and reticulocyte number and an XT-2000IV automated hematology analyzer ( Sysmex Corporation, Japan). On the last day of treatment, approximately 6 hours after dosing, blood was collected from the abdominal aorta in Venoject II vacuum heparinized tubes (Terumo Corporation, Japan). After centrifugation at 4°C and 3000 rpm (about 197g) for 15 minutes, plasma was collected to measure EPO concentration with a Mouse/Rat Immunoassay (R&D Systems).

The erythropoietic effect of roxadustat was also investigated in normal cynomolgus monkeys. All procedures were carried out at Covance Laboratories, Inc. (Vienna, VA) in accordance with the US Food and Drug Administration Good Laboratory Practice Regulations, Title 21 of the US Code of Federal Regulations Part 58. Male and female monkeys were housed individually in stainless-steel cages. Animals were offered Certified Primate Diet number 2055C (Harlan Teklad) once or twice daily. Water was provided ad libitum. Environmental controls for the animal room were set to maintain 15–29 °C, a relative humidity of 30% –70%, a minimum of 10 room air changes per hour, and a 12-hour light/dark cycle. The light/dark cycle was interrupted on occasion for study-related activities. In total, 25 male and 25 female cynomolgus monkeys weighing 1.9–2.5 kg were used. Blood samples were collected via venipuncture from the femoral vein of nonseparated conscious animals. The animals were randomly assigned to 0, 3, 10, 20, or 30 mg/kg roxadustat, with five animals per sex per group. Animals were orally dosed intermittently (three times per week) for 52 weeks. Blood samples were collected to measure blood Hb concentration and hematocrit with a Siemens Advia 120 twice prior to the first dose and at regular intervals during the 52 weeks of treatment.

Pharmacokinetic parameters for roxadustat were determined in normal male and female cynomolgus monkeys (n = 3 per group per sex) from a non-naive pharmacokinetic colony using a complete-crossover design under overnight fasting conditions (Covance, Madison, WI). All procedures were in compliance with the Animal Welfare Act regulations (Title 9 of the US Code of Federal Regulations Part 58). Animals were individually housed in stainless-steel cages for the duration of the study. At the time of dosing, body weight ranged from 3.0 to 4.1 kg and were from 2.9 to 3.4 kg for females. A dose of 30 mg/kg was administered orally by gavage in a volume of 5 ml/kg (6 mg/ml suspension in 0.5% sodium carboxymethylcellulose and 0.1% Tween 80). The same dose was administered intravenously as a slow bolus infusion over approximately 3 minutes via a saphenous vein at 3 ml/kg (10 mg/ml solution in PBS with pH adjusted by NaOH for solubility). Blood samples were collected at regular intervals for up to 96 hours postdose for determination of plasma roxadustat concentration by liquid chromatography-mass spectrometry.

**Rat Model of Anemia After Five-Sixth Nephrectomy.** Male Sprague-Dawley rats (Charles River Laboratories, Hollister, CA) were used to determine the erythropoietic effects of roxadustat in an anemia model of kidney injury induced by five-sixth nephrectomy. All procedures were performed in the animal facility at FibroGen, Inc. and were approved by the Institutional Animal Care and Use Committee at FibroGen, Inc. Animals were housed in pairs in standard shoebox-style rat cages. Fluorescent lighting was provided for 12 hours per day between 7:00 AM and 7:00 PM. Temperature was maintained between 20 and 22°C, and humidity was maintained between 40% and 70%. Rodent Laboratory Diet (catalog number 5001; PMI Feeds, Inc.) and tap water were available ad libitum. Animals weighed approximately 300 g at study initiation. Rats were anesthetized with isoflurane (Isoflo; Patterson Veterinary, Dinuba, CA), and a midline abdominal incision was made under sterile conditions followed by blunt dissection of the renal pedicles. Two or three branches of the left renal artery were ligated to infarct two-thirds of the kidney, as indicated by a change in kidney color. The right kidney was then removed, and the abdominal incision was closed. Sham animals underwent the same procedure without left renal artery ligation and right nephrectomy. Animals recovered for 5 weeks until anemia and kidney dysfunction developed, as assessed by complete blood cell count (Cell-Dyn 3700; Abbott Diagnostics, Abbott Park, IL) and serum concentrations of blood urea nitrogen (BUN) and creatinine (Quality Clinical Laboratories, Mountain View, CA). Nephrectomized animals were then assigned to treatment with vehicle or roxadustat such that all groups had similar mean baseline body weight, hematocrit, Hb, and serum creatinine. Sham animals were similarly assigned to groups. Nephrectomized animals were treated orally by gavage three times per week for 1 week, followed by twice per week for a 2nd week with vehicle or with 20 or 40 mg/kg roxadustat (FibroGen, Inc.) formulated in 0.5% sodium carboxymethylcellulose (Spectrum Chemical) and 0.1% polysorbate 80 (Avantor Performance Materials) (n = 8 to 9 per group). Sham animals were treated with vehicle or 20 mg/kg of roxadustat using the same dosing regimen as nephrectomized animals (n = 8 per group). Venous blood samples were collected after 7 and 14 days of treatment of blood cell count and serum chemistry analysis.

**Nonclinical Profile of Roxadustat for Anemia**

Nonclinical studies were performed to determine the potential of adverse effects of roxadustat in various species, including cynomolgus monkeys, Lewis rats, female hamsters, and Female Lewis rats (Harlan Laboratories, Indianapolis, IN) were used to determine the erythropoietic effect of roxadustat in a model of anemia of inflammation. All procedures were performed in the animal facility at FibroGen, Inc., and were approved by the Institutional Animal Care and Use Committee at FibroGen, Inc. Animals were individually housed in standard shoebox-style rat cages. Fluorescent lighting was provided for 12 hours per day between 7:00 AM and 7:00 PM. Temperature was maintained between 20 and 22°C, and humidity was maintained between 35% and 50%. Purina Rodent Chow (catalog number 5001; PMI Nutrition International, Inc., Brentwood, MO) and tap water were available ad libitum. Animals weighed 153–176 g at study initiation. PG-PS polymers from Streptococcus pyogenes (PG-PS 108; Lee Laboratories, Grayson, GA) were administered intraperitoneally in physiologic saline at 15 mg/kg of rhamnose to induce anemia. Sham (unchallenged) animals were administered physiologic saline. Four weeks after injection of PG-PS, complete blood cell count was determined (Cell-Dyn 3700; Abbott Diagnostics), and animals were assigned to treatment groups such that all PG-PS–challenged groups had similar mean baseline hematocrits. PG-PS–challenged animals with hematocrit above 35% were considered nonresponsive and were not used in the study. Unchallenged animals were similarly assigned to groups. Animals were then treated orally by gavage three times per week with 30 mg/kg roxadustat formulated in 0.5% sodium carboxymethylcellulose (Spectrum Chemical) and 0.1% polysorbate 80 (Avantor Performance Materials) (n = 8 PG-PS–challenged; n = 4 unchallenged) or vehicle (n = 8 PG-PS–challenged; n = 4 unchallenged). Animals were also treated intravenously with darbepoetin alfa (Aranesp; Amgen, Thousand Oaks, CA) every other week at 30 μg/kg (n = 7 PG-PS–challenged; n = 4 unchallenged) or sodium ferric gluconate complex (Ferrlecit; Watson Pharma) once per week at 1.5 mg/kg (n = 7 PG-PS–challenged; n = 4 unchallenged). Venous blood samples were collected after 14 and 28 days of treatment for blood cell count and after 28 days for serum iron and cytokine measurements. A multiplex cytokine panel was run for IL-1α, IL-1β, IL-4, TNFα, granulocyte-macrophage colony-stimulating factor, IL-6, and macrophage inflammatory protein (MIP)-3α on serum samples. After the last blood sample, animals were euthanized, and their front paws were harvested and weighed to quantify inflammation. Liver and duodenum were harvested and processed for quantitative real-time PCR.
Gene Expression Analysis. Liver and duodenum tissue samples were stored in Ambion RNAlater solution (Thermo Fisher Scientific). RNA was isolated by homogenization in Trizol (Invitrogen) and further purified on RNAeasy96 columns (Qiagen, Germany). Complementary DNA was prepared from total RNA using Omniscript reverse transcriptase (Qiagen) and random hexamer primers. Quantitative real-time PCR was performed in a Prism 7000 (Applied Biosystems, Foster City, CA) instrument using TaqMan Universal PCR Master Mix (Applied Biosystems) and TaqMan Assays-on-Demand (Applied Biosystems) assays. Quantitative PCR data for the duodenal cytochrome b gene (Dcytb), Dmt1 (also known as Slc11a2, iron transporter DMT1 gene), and Hamp (hepcidin gene) were normalized to 18S ribosomal RNA expression.

Statistics. All in vitro data are presented as means ± S.D. Data from cell-based studies were analyzed using ANOVA followed by Dunnett’s multiple comparison test. All in vivo data are presented as means ± S.E.M. Data from in vivo studies were analyzed using ANOVA followed by a multiple comparison procedure at each time point (Student-Newman-Keuls method). Steel’s test was performed to analyze in vivo EPO results. When values of EPO were below the lower limit of quantification (47.0 pg/ml), the lower limit of quantification was used for statistical analysis. A P value less than 0.05 was considered statistically significant for all tests.

Results

Roxadustat is an Inhibitor of HIF-PH Enzymes that Reversibly Stabilizes HIF-1α and HIF-2α. Roxadustat (FG-4592) was selected from a series of 4-hydroxyisouquinoline glycinamides that were designed to inhibit HIF-PH enzymes by competing with the substrate αKG. The ability of roxadustat to inhibit recombinant full-length human HIF-PH enzymes was measured using an enzyme assay based on the decarboxylation of 14C-labeled αKG and the production of 14CO2 (Zhang et al., 1999). In the presence of 100 μM αKG, 1 μM Fe3+, and 1 mM ascorbate, roxadustat IC50 values of 1.04 ± 0.46, 1.74 ± 0.73, and 0.36 ± 0.12 μM were obtained for PHD1, PHD2, and PHD3, respectively (mean ± S.D., n = 9 to 10). The dependence of PHD2 activity on αKG concentration at several concentrations of roxadustat yielded invariable Vmax and variable Km, indicating competitive inhibition kinetics with respect to αKG and a Ki value for roxadustat of 20 ± 3 nM (Supplemental Fig. 1; Supplemental Table 1). The selectivity of roxadustat for the HIF-PH enzymes over FIH was determined by measuring roxadustat’s ability to inhibit recombinant full-length human FIH under the same assay conditions as those used for the HIF-PH enzymes. Under those conditions, the FIH IC50 for roxadustat was >150 μM.

The ability of roxadustat to stabilize HIF-α was explored in two human cell lines: Hep3B hepatoma cells and HK-2 renal proximal tubule cells. In both lines, incubation with roxadustat for 3 hours dose-dependently increased HIF-1α and HIF-2α protein levels (Fig. 1A; Supplemental Fig. 2, A and B). The reversibility of HIF-α stabilization by roxadustat was investigated by performing washout studies in Hep3B cells. Compared with DMSO-treated cells, Hep3B cells treated with 30 μM roxadustat for 3 hours and then harvested immediately exhibited an accumulation of HIF-1α protein. In cells treated with roxadustat for 3 hours and harvested at 15, 30, or 60 minutes after washout of the drug, HIF-1α levels rapidly decreased back to basal levels (Fig. 1B; Supplemental Fig. 2C). A reduction in HIF-1α protein was observed 15 minutes after washout, and by 60 minutes, HIF-1α was no longer detectable.

Roxadustat Stimulates EPO Production in Cells and Overcomes the Suppressive Effects of Inflammatory Cytokines. The ability of roxadustat to increase production of EPO, a well known HIF target gene, was investigated in Hep3B cells. Exposure of Hep3B cells to roxadustat dose-dependently increased EPO protein secreted into the culture supernatant (Fig. 2A). EPO production is suppressed by proinflammatory cytokines, such as TNFα and IL-1β (Jelkmann et al., 1994; La Ferla et al., 2002). We found that both of these cytokines dose-dependently decreased EPO protein secreted by Hep3B cells (Fig. 2, B and C). We explored whether roxadustat could overcome this suppressed EPO production. Hep3B cells were treated with increasing concentrations of roxadustat in the presence of either 0.125 ng/ml TNFα or 0.125 ng/ml IL-1β, concentrations that robustly suppress EPO production (Fig. 2, B and C). Even in the presence of these proinflammatory cytokines, roxadustat dose-dependently increased EPO production from Hep3B cells (Fig. 2, D and E).

Pharmacokinetics of Roxadustat and Time Course of EPO Secretion in Rats and Monkeys. When dosed intravenously at 20 mg/kg in rats and 30 mg/kg in monkeys, roxadustat showed low systemic clearances in rats and monkeys that were much lower than hepatic blood flow, and
apparent volumes of distribution at steady state (Vdss, 134–178 ml/kg) that were larger than plasma volume but less than total body water (Table 1). Oral bioavailability was high in both species (70%–100%). Plasma roxadustat peaked 2 hours after a 30-mg/kg oral dose in rats, whereas maximum plasma EPO concentration was achieved 8–12 hours postdose (Fig. 3).

Twenty-four hours after dosing, roxadustat plasma concentrations were at low levels (less than 5% of $C_{\text{max}}$), and EPO levels were close to baseline levels.

**Roxadustat Increases Circulating EPO Concentration and Erythropoiesis in Normal Rats.** The in vivo erythropoietic effect of roxadustat was evaluated in normal rats at doses ranging from 6.25 to 50 mg/kg that were administered three times per week for 29 days. Blood Hb concentration and hematocrit gradually increased over time in a dose-dependent manner (Fig 4, A and B). The 12.5-mg/kg dose induced a modest 0.9-g/dl rise in Hb over vehicle by day 29, whereas the high dose (50 mg/kg) increased Hb by 5.8 g/dl compared with vehicle. Reticulocytes also increased in a dose-dependent manner, and maximum responses were seen on days 4 and 8 of treatment in the 25- and 50-mg/kg groups, respectively (Fig. 4C). Reticulocytes gradually returned to vehicle levels in the 25-mg/kg group, but they remained elevated compared with the vehicle group after 29 days of treatment with 50 mg/kg. Plasma EPO concentrations after 29 days of treatment with 12.5, 25, and 50 mg/kg roxadustat were significantly higher than in the vehicle group (Fig 4D). Plasma EPO was more than seven times higher in the 12.5-mg/kg group than in the vehicle group, whereas it was more than 300 times higher in the 50-mg/kg group than in the

### TABLE 1
Summary of the pharmacokinetics of roxadustat

<table>
<thead>
<tr>
<th>Species</th>
<th>CL (mL/h per kilogram)</th>
<th>Vdss (mL/kg)</th>
<th>$t_{1/2}$ (h)</th>
<th>Oral F (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat$^a$</td>
<td>33.7 ± 2.7</td>
<td>178 ± 19</td>
<td>3.6 ± 1.4</td>
<td>100</td>
</tr>
<tr>
<td>Monkey$^b$</td>
<td>55.7 ± 12.2</td>
<td>134 ± 32</td>
<td>10.8 ± 1.3</td>
<td>70 ± 17</td>
</tr>
</tbody>
</table>

$^a$Twenty milligrams per kilogram dose, n = 4 (male) per group, oral F from non-crossover design.

$^b$Thirty milligrams per kilogram dose, n = 6 (three males and three females) per group, oral F from crossover design. CL, clearance; Oral F, oral bioavailability; Vdss, apparent volume of distribution at steady state.
vehicle group. EPO concentration was below the lower limit of quantification in all vehicle-treated animals and in seven of eight animals in the 6.25-mg/kg group.

**Roxadustat Increases Erythropoiesis in Normal Cynomolgus Monkeys.** In a 52-week intermittent-dosing study in male and female cynomolgus monkeys, Hb was measured prior to the first dose and at regular intervals during the dosing period. Monkeys administered $20 \text{mg/kg}$ roxadustat three times per week exhibited increased erythropoiesis, with significant increases in Hb apparent after 2 weeks of dosing (Fig. 5A). The transient decrease in Hb observed in all groups during the 1st week of treatment was due to multiple bleeds performed in the days preceding the Hb measurement to assess drug exposure. Red blood cell count was also significantly elevated at doses $\geq 20 \text{mg/kg}$ (Fig. 5B).

**Roxadustat Corrects Anemia in Rats after Five-Sixth Nephrectomy.** The erythropoietic activity of roxadustat was determined in a rat model of anemia of CKD induced by five-sixth nephrectomy. Nephrectomy resulted in anemia, as shown by lower Hb (Fig. 6A), hematocrit (Fig. 6B), and red blood cell count (Fig. 6C) than sham surgery. Nephrectomized animals also had higher levels of BUN and serum creatinine than sham animals, indicating progressive kidney failure (Supplemental Fig. 3). After 2 weeks of intermittent dosing, treatment with 20 and 40 mg/kg roxadustat significantly increased and normalized Hb (Fig. 6A), hematocrit (Fig. 6B), and red blood cell count (Fig. 6C) in nephrectomized animals compared with the vehicle control group. BUN and serum creatinine values were not affected by treatment with roxadustat (Supplemental Fig. 3).

**Roxadustat Corrects Anemia of Inflammation in a Rat Model of ACD.** The efficacy of roxadustat in correcting anemia was investigated in a rat model of PG-PS–induced chronic inflammation. Hb was below 10 g/dl in all PG-PS-challenged groups before treatment initiation, indicating severe anemia (Fig. 7A). Mean corpuscular volume (MCV, Fig. 7B) and mean corpuscular Hb concentration (MCHC, Fig. 7C) were also reduced in anemic animals, indicating microcytosis and hypochromia, respectively.

Treating anemic PG-PS-challenged animals with 30 mg/kg roxadustat three times per week for 4 weeks increased their Hb to levels similar to nonchallenged animals administered vehicle (Fig. 7A). Roxadustat also improved the microcytosis (increased MCV, Fig. 7B) and hypochromia (increased MCHC, Fig. 7C) observed in the PG-PS–challenged groups. In contrast, darbepoetin and intravenous iron had no effect on Hb, MCV, or MCHC in anemic PG-PS–challenged animals.

In nonchallenged animals, treatment with either roxadustat or darbepoetin produced a robust erythropoietic response. After 2 weeks of treatment with roxadustat or darbepoetin, Hb was significantly higher than in the vehicle group, and the erythropoietic response was maintained at 4 weeks with both treatments (Fig. 7A). Intravenous iron had no effect on erythropoiesis in nonchallenged animals (Fig. 7A).

**Roxadustat Does Not Affect the Inflammatory Response in a Rat Model of ACD.** Animals challenged with PG-PS developed an inflammatory response. These animals exhibited increased circulating white blood cells (WBCs),
including monocytes (Supplemental Fig. 4, A and B), neutrophils, lymphocytes, and eosinophils (data not shown). These animals also displayed increased paw weight, suggesting that they developed arthritis (Supplemental Fig. 4C). Treatment with roxadustat significantly decreased the monocyte count (Supplemental Fig. 4B) but did not affect other WBC types (data not shown). Darbepoetin and intravenous iron had no effect on the WBC response in PG-PS–challenged animals. Paw weight was not significantly affected by any of the treatment regimens (Supplemental Fig. 4C).

A multiplex cytokine panel was run on serum samples taken after 4 weeks of treatment. Values for IL-1β, IL-4, TNFα, and granulocyte-macrophage colony-stimulating factor were below the levels of quantitation in most samples (data not shown). IL-6 was primarily measurable in samples from PG-PS–challenged animals, and MIP-3α was measurable in nearly all samples. IL-6 and MIP-3α levels were not significantly reduced after treatment with roxadustat in PG-PS–challenged animals, although the data suggest a trend decline. Serum IL-6 was increased in the darbepoetin group, and intravenous iron had no effect on serum cytokines (Supplemental Fig. 4D).

**Roxadustat Improves Iron Metabolism in a Rat Model of ACD.** At the end of the ACD study, PG-PS–challenged animals treated with vehicle had lower serum iron (Fig. 8A) and transferrin saturation (Fig. 8B), as well as higher total iron–binding capacity (a measure of serum transferrin level, Fig. 8C), than vehicle-treated animals not challenged with PG-PS. In PG-PS–challenged animals, roxadustat significantly improved serum iron levels (Fig. 8A) and transferrin saturation (Fig. 8B) without affecting total iron–binding capacity (Fig. 8C) compared with vehicle. Neither darbepoetin nor intravenous iron had any significant effect on iron parameters compared with vehicle.

Quantitative PCR was used to quantify hepatic gene expression of *Hamp* (which encodes the protein hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation) and duodenal gene expression of *Dcytb* (a ferric reductase enzyme required for intestinal absorption of iron) and *Dmt1* (a transporter of iron through apical membranes). Roxadustat reduced expression of hepatic *Hamp* (Fig. 9A) in PG-PS–challenged animals and increased expression of *DcytB*...
(Fig. 9B) and Dmt1 (Fig. 9C) in the duodenum of PG-PS–challenged animals. Darbepoetin and intravenous iron had no significant effect on Hamp, DcytB, or Dmt1 expression.

**Discussion**

Several HIF-PI inhibitors are being evaluated in clinical trials as novel therapeutics to treat anemia of CKD (Gupta and Wish, 2017; Del Vecchio and Locatelli, 2018). In December 2018, roxadustat became the first HIF-PI inhibitor to receive marketing approval in any country when China’s National Medical Products Administration approved it for the treatment of anemia of CKD in dialysis-dependent patients (Dhillon, 2019). We present here the pharmacological profile of roxadustat, an inhibitor of HIF-PI enzymes with similar potency for all three isoforms (PHD1, PHD2, and PHD3). The IC50 values for PHD1–3 were between 0.36 and 1.74 μM under our assay conditions. Roxadustat displays competitive inhibition kinetics with respect to αKG, and therefore, the αKG concentration in the enzyme reaction will significantly influence the calculated IC50. We chose 100 μM αKG for our enzyme assays based on published reports of intracellular αKG concentrations (Nagai et al., 1998; MacKenzie et al.,...
would be expected to yield lower IC50 values (Yeh et al., 2017).

In cells, both HIF-1α and HIF-2α were stabilized by roxadustat at concentrations as low as 3 μM, consistent with the observation that roxadustat inhibits all three HIF-PH enzymes. HIF-α protein levels rapidly declined after washout of roxadustat from cell cultures, indicating that HIF-PH inhibition is reversible and that once the drug is removed, hydroxylation and degradation of HIF-α subunits quickly resumes.

Although HIF-1 was initially identified as the transcription factor responsible for the hypoxic induction of EPO (Semenza and Wang, 1992; Wang and Semenza, 1995; Wang et al., 1995), studies in mice and analysis of genetic mutations in patients with inherited polycythemia have since revealed that HIF-2 is the main regulator of EPO production (Rankin et al., 2007; Percy, 2008; Kapitsinou et al., 2010). In our studies, stabilization of HIF-2α in Hep3B cells by roxadustat was accompanied by a dose-dependent increase in EPO production. HIF-2 also modulates intestinal iron uptake by regulating expression of DMT1 and DCYTB (Mastroiannaki et al., 2009, 2012; Shah et al., 2009). However, other HIF-regulated genes involved in iron metabolism and erythropoiesis appear to depend more on HIF-1 than on HIF-2 (Rolfs et al., 1997; Tacchini et al., 1999; Zhang et al., 2011), suggesting that stabilization of both HIF-2α and HIF-1α is desirable for an optimal erythropoietic response.

Roxadustat exhibits considerable selectivity for the HIF-PH enzymes over the asparaginyl hydroxylase FIH, with an IC50 > 150 μM for FIH compared with 0.36–1.74 μM for PHD1–3. Hydroxylation of HIF-α by FIH blocks the interaction between HIF-α and the p300/CBP family of coactivators and, as a result, limits the transcriptional activity of HIF (Mahon et al., 2001; Lando et al., 2002a,b). Certain HIF target genes are sensitive to FIH hydroxylation of HIF-α and are not optimally induced unless both HIF-PH enzymes and FIH are inhibited. Conversely, a subset of HIF target genes are relatively insensitive to FIH activity and can be induced by HIF-PH inhibition alone (Dayan et al., 2006; Chan et al., 2016). Because roxadustat inhibits HIF-PH enzymes but not FIH, the compound likely elicits a more limited HIF transcriptional response than conditions in which both HIF-PH and FIH are suppressed, such as severe hypoxia (Chan et al., 2016). The proangiogenic gene vascular endothelial growth factor (VEGF) is an example of an FIH-inhibited HIF target gene (Dayan et al., 2006). No increase in the risk of neoplasia was observed in nonclinical carcinogenicity studies and in VEGF-dependent tumor models (Beck et al., 2017; Seeley et al., 2017). Furthermore, changes in systemic VEGF levels with HIF-PH inhibitors such as roxadustat have not been reported in phase 2a studies (Locatelli et al., 2017).

Pharmacokinetic studies showed that roxadustat exhibited low clearance, high oral bioavailability, and half-lives of approximately 4 hours in rats and 11 hours in monkeys. Roxadustat administered orally three times per week to healthy rats for 29 days increased circulating EPO levels, blood Hb, hematocrit, and reticulocytes in a dose-dependent manner. The increase in reticulocyte count was maximal 4–8 days after initiation of treatment. Blood Hb and hematocrit rose steadily over the 29 days of dosing. EPO plasma concentration peaked 6–10 hours after peak drug plasma level, consistent with upregulation of gene expression and protein synthesis. Plasma EPO levels remained elevated for a few hours and declined to baseline 24 hours after dosing, showing that transient stimulation of EPO production by intermittent dosing is sufficient for significant erythropoiesis to occur. Roxadustat was equally effective when administered intermittently to cynomolgus monkeys.

We studied the effect of roxadustat on anemia associated with chronic renal failure using five-sixth nephrectomized rats. This model is commonly used to study CKD and its complications, including anemia (de Mik et al., 2013; Garrido et al., 2015; Ribeiro et al., 2016). Roxadustat, administered for 2 weeks (20 and 40 mg/kg) in nephrectomized rats, dose-dependently normalized Hb, hematocrit, and red blood cell count compared with control rats. In the clinical setting, roxadustat increased blood Hb in anemic CKD patients (Besarab et al., 2015, 2016; Provenzano et al., 2016a; Chen et al., 2019a,b).

Inflammatory cytokines such as TNFα and IL-1β suppress EPO production in cell culture and in isolated perfused rat
kidneys (Jelkmann et al., 1994; La Ferla et al., 2002). This suppression may contribute to the pathophysiology of anemia of CKD. In Hep3B cells, we observed a decrease in EPO production after exposure to either TNF-α or IL-1β. Despite the suppression of basal EPO production by these inflammatory cytokines, roxadustat induced a dose-dependent increase in EPO in the presence of TNF-α and IL-1β.

The erythropoietic activity of roxadustat in the context of inflammation and impaired iron metabolism was evaluated in a rat model of anemia of inflammation induced by PG-PS. Four weeks of oral treatment with 30 mg/kg roxadustat three times per week corrected PG-PS–induced anemia in rats. Roxadustat also improved iron use, as shown by amelioration of microcytosis and hypochromia in PG-PS–injected animals. Serum iron and transferrin saturation were also mildly, but significantly, elevated, indicating improved mobilization of iron stores to support erythropoiesis. Hepcidin is a key regulator of iron metabolism and a mediator of anemia of inflammation (Deicher and Hör, 2004). Roxadustat significantly decreased Hamp mRNA (hepcidin) expression in liver, which may explain the improved iron status and hematology observed in PG-PS–injected animals treated with roxadustat. Intestinal iron absorption by duodenal enterocytes requires DCYTB to reduce ferric iron to ferrous iron (Fe^{2+}) and DMT1 to transport Fe^{2+} through apical membranes. Roxadustat significantly increased DcytB and Dmt1 mRNA in the duodenum of PG-PS–injected animals, pointing to a potential mechanism by which iron availability is improved, consistent with HIF activation (Haase, 2010; Anderson et al., 2011). Roxadustat had little effect on inflammation in this model, indicating that the anemic properties of roxadustat were not due to inhibition of the inflammatory response induced by PG-PS.

Conversely, the EPO analog darbepoetin administered every other week increased erythropoiesis in normal animals over a 4-week period but did not correct anemia of inflammation in the PG-PS model. The lack of efficacy of EPO analogs in this model was previously reported with recombinant human EPO (Barrett et al., 2011, 2015). These results indicate that darbepoetin is not as efficacious in stimulating erythropoiesis in the context of inflammation as in normal animals. Darbepoetin, unlike roxadustat, had no significant effect on iron metabolism, including serum iron, transferrin saturation, and mRNA expression of Hamp, DcytB, or Dmt1. These results may explain darbepoetin’s lack of efficacy in this anemia model of functional iron deficiency (Sartor et al., 1989). Finally, the lack of effect of intravenous iron therapy in this study agrees with the functional iron deficiency seen in the PG-PS model. Iron supplementation alone could not overcome iron sequestration in these animals.

In clinical trials, roxadustat administered intermittently corrected anemia in CKD patients independently of iron or inflammatory status (Besarab et al., 2016; Provenzano et al., 2016a). It also reduced serum hepcidin levels and increased serum transferrin concentrations, improving iron delivery to bone marrow (Besarab et al., 2016; Chen et al., 2019a). Because roxadustat improved iron status, intravenous iron supplementation was not required for efficacy, in contrast to treatment with ESAs (Besarab et al., 2015; Provenzano et al., 2016a). Inflammation in patients with CKD is associated with hyporesponsiveness to ESAs, and the link between hyporesponsiveness and inflammation may be functional iron deficiency due to elevated hepcidin (MacDougall and Cooper, 2005; Adamson, 2009; Yilmaz et al., 2011). The coordinated erythropoiesis resulting from both increased EPO secretion and improved iron status explains the efficacy of roxadustat against anemia in the context of inflammation. It also accounts for the correction of anemia by roxadustat with relatively low concentrations of circulating endogenous EPO compared with the supraphysiologic serum EPO levels achieved after treatment with ESAs (Besarab et al., 2015; Provenzano et al., 2016b).

In conclusion, roxadustat inhibits all three HIF-PH isoforms, stabilizes HIF-1α and HIF-2α, and dose-dependently increases EPO production in vitro, both in the absence and presence of inflammatory cytokines. Roxadustat exhibits erythropoietic activity in normal rats and monkeys and corrects anemia in rat models of CKD and of chronic inflammation with impaired iron metabolism. The coordinated erythropoietic response induced by roxadustat involving both increased EPO secretion and mobilization of iron stores makes this drug a promising treatment of anemia of CKD and anemia associated with functional iron deficiency.

Acknowledgments

The authors would like to thank Jenny Charan and Crystal Herron for editing the manuscript for submission. Roxadustat is being developed by FibroGen, Inc., AstraZeneca, and Astellas Pharma. The authors would like to thank Anja Slikkerveer (Astellas), Gerald Koelsh (Astellas), Tobru Uguwa (Astellas), Krister Bamberg (AstraZeneca), and Mike Rolf (AstraZeneca) for their support with the editing and reporting of this manuscript.

Authorship Contributions

Participated in research design: del Balzo, Signore, Walkinshaw, Seeley, Brenner, Wang, Guo, Flippin, Chow, Langsetmo, Guenzler, Liu, Klaus, Lin, Neff.

Conducted experiments: Wang, Guo, Arend, Chow, Gervasi, Kjaergaard, Langsetmo.


Wrote or contributed to the writing of the manuscript: del Balzo, Signore, Walkinshaw.

References


Nonclinical Profile of Roxadustat for Anemia


